67 related articles for article (PubMed ID: 36594100)
1. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer.
Ma G; Wang J; Fu J; Chen R; Liang M; Li M; Xia T; Liu X; Wang S
Breast Cancer Res Treat; 2023 Aug; 201(1):27-41. PubMed ID: 37311933
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.
Hashimoto K; Ochiya T; Shimomura A
Breast Cancer; 2024 Mar; ():. PubMed ID: 38512533
[TBL] [Abstract][Full Text] [Related]
3. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles.
Fahmy SA; Mahdy NK; Mohamed AH; Mokhtar FA; Youness RA
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396746
[TBL] [Abstract][Full Text] [Related]
4. METTL14/miR-29c-3p axis drives aerobic glycolysis to promote triple-negative breast cancer progression though TRIM9-mediated PKM2 ubiquitination.
Wu H; Jiao Y; Guo X; Wu Z; Lv Q
J Cell Mol Med; 2024 Feb; 28(3):e18112. PubMed ID: 38263865
[TBL] [Abstract][Full Text] [Related]
5. Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting.
Saikia M; Cheung N; Singh AK; Kapoor V
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240085
[TBL] [Abstract][Full Text] [Related]
6. The Role of MicroRNAs in the Chemoresistance of Breast Cancer.
Wang J; Yang M; Li Y; Han B
Drug Dev Res; 2015 Nov; 76(7):368-74. PubMed ID: 26310899
[TBL] [Abstract][Full Text] [Related]
7. The Link between Diabetes, Pancreatic Tumors, and miRNAs-New Players for Diagnosis and Therapy?
Kozłowska M; Śliwińska A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373398
[TBL] [Abstract][Full Text] [Related]
8. miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells.
Han X; Li M; Xu J; Fu J; Wang X; Wang J; Xia T; Wang S; Ma G
Int J Biol Sci; 2023; 19(1):89-103. PubMed ID: 36594100
[TBL] [Abstract][Full Text] [Related]
9. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
12. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
13. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.
Bahena-Ocampo I; Espinosa M; Ceballos-Cancino G; Lizarraga F; Campos-Arroyo D; Schwarz A; Maldonado V; Melendez-Zajgla J; Garcia‐Lopez P
EMBO Rep; 2016 May; 17(5):648-58. PubMed ID: 27113763
[TBL] [Abstract][Full Text] [Related]
14. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy: From Discovery to Clinical Application.
Alix-Panabières C; Pantel K
Cancer Discov; 2021 Apr; 11(4):858-873. PubMed ID: 33811121
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
